Negligence and fraud by investigators during a drug study are sometimes serious violations of sponsor contracts and other scientific obligations. Examples are provided of fraud, negligence, and other bad faith efforts detected during Food and Drug Administration (FDA) inspections and sponsor-initiated site audits.
ShapiroMF. Data Audits in Investigational Drug Trials and Their Implications for Detection of Misconduct in Science. In Fraud and Misconduct in Medical Research.LockSWellsF, Eds. London: BMJ Publishing Group; 1993.
2.
BrockP. A Pharmaceutical Company's Approach to the Threat of Research Fraud. In Fraud and Misconduct in Medical Research.LockSWellsF, Eds. London: BMJ Publishing Group; 1993.
3.
FisherB. Correspondence: Fraud in Breast Cancer Trials. New Eng J Med.1994;330:1458.
4.
AltmanL. The Doctor's World. The New York Times. April 12, 1994.
5.
KracovDA. United States v. Garfinkel: Expanding Criminal Liability for Clinical Investigators. App Clin Trials.1995;4:34–38.
6.
MackintoshDR. Building Quality Assurance into Clinical Trials. App Clin Trials.1993;2:42–49.
7.
HodgesC. GCP Guidelines Combat Fraud in Clinical Research. World Pharmaceuticals Report.1992;11.
8.
HodgesC. Investigating, Reporting and Pursuing Fraud in Clinical Research: Legal Aspects and Options in England and Wales. In Fraud and Misconduct in Medical Research.LockSWellsF, Eds. London: BMJ Publishing Group; 1993.
9.
KassirerJP. The Frustrations of Scientific Misconduct. New Eng J Med.1993;328:1634–1637.
10.
DingellJD. Shattuck Lecture — Misconduct in Medical Research. New Eng J Med.1993;328: 1610–1615.
